PharmGen Science Inc
KRX:004720
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PharmGen Science Inc
Operating Income
PharmGen Science Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PharmGen Science Inc
KRX:004720
|
Operating Income
₩8.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
74%
|
CAGR 10-Years
14%
|
|
|
Yuhan Corp
KRX:000100
|
Operating Income
₩104.4B
|
CAGR 3-Years
43%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Operating Income
₩203.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Operating Income
₩257.8B
|
CAGR 3-Years
18%
|
CAGR 5-Years
39%
|
CAGR 10-Years
2%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Operating Income
₩8.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-9%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Operating Income
₩20.4B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
PharmGen Science Inc
Glance View
PharmGen Science, Inc. engages in the development and production of medicaments. The company is headquartered in Hwaseong, Gyeonggi-Do. The Company’s products include antiepileptic agents, anti-inflammatory agents, antiphlogistic agents, central nervous system agents, urinary agents, antihistamine agents, antivirus agents, agents for bones, agents for livers, calcium agents, antibiotics, diabetes agents, respiratory agents, as well as over-the-counter (OTC) drugs, obesity drugs, health food and others. In addition, the Company is also engaged in the manufacturing, wholesale and retail distribution of functional cosmetics. The firm distributes its products within domestic market and to overseas markets.
See Also
What is PharmGen Science Inc's Operating Income?
Operating Income
8.6B
KRW
Based on the financial report for Sep 30, 2025, PharmGen Science Inc's Operating Income amounts to 8.6B KRW.
What is PharmGen Science Inc's Operating Income growth rate?
Operating Income CAGR 10Y
14%
Over the last year, the Operating Income growth was -33%. The average annual Operating Income growth rates for PharmGen Science Inc have been 11% over the past three years , 74% over the past five years , and 14% over the past ten years .
